Your browser doesn't support javascript.
loading
Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes.
Kuksa, L; Riekstina, V; Leimane, V; Ozere, I; Skenders, G; Van den Bergh, R; Kremer, K; Acosta, C D; Harries, A D.
Affiliation
  • Kuksa L; Riga East University Hospital TB and Lung Disease Centre, Riga, Latvia ; Riga Stradins University, Riga, Latvia.
  • Riekstina V; Riga East University Hospital TB and Lung Disease Centre, Riga, Latvia.
  • Leimane V; Riga East University Hospital TB and Lung Disease Centre, Riga, Latvia.
  • Ozere I; Riga East University Hospital TB and Lung Disease Centre, Riga, Latvia ; Riga Stradins University, Riga, Latvia.
  • Skenders G; Riga East University Hospital TB and Lung Disease Centre, Riga, Latvia.
  • Van den Bergh R; Medical Department, Operational Center Brussels, Médecins Sans Frontières, MSF-Luxembourg, Luxembourg.
  • Kremer K; Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, Health Security & Environment, World Health Organization Regional Office for Europe, Copenhagen, Denmark.
  • Acosta CD; Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, Health Security & Environment, World Health Organization Regional Office for Europe, Copenhagen, Denmark.
  • Harries AD; International Union Against Tuberculosis and Lung Disease, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK.
Public Health Action ; 4(Suppl 2): S47-53, 2014 Oct 21.
Article in En | MEDLINE | ID: mdl-26393098
ABSTRACT

SETTING:

Drug-resistant tuberculosis (TB) is an important public health problem in Latvia.

OBJECTIVE:

To document trends, characteristics and treatment outcomes of registered patients with multi-drug-resistant (MDR-) and extensively drug-resistant (XDR-) TB in Latvia from 2000 to 2010.

DESIGN:

A retrospective national cohort study.

RESULTS:

Of 1779 patients, 1646 (92%) had MDR- and 133 (8%) XDR-TB. Over 11 years, the proportion of XDR-TB among MDR-TB patients increased from 2% to 18%. Compared to MDR-TB patients, those with XDR-TB were significantly more likely to have failed MDR-TB treatment (OR 8.4, 95%CI 4.3-16.2), have human immunodeficiency virus infection (OR 3.2, 95%CI 1.8-5.7), be illegal drug users (OR 5.7, 95%CI 2.6-11.6) or have had contact with MDR-TB patients (OR 1.9, 95%CI 1.3-2.8). Cure rates for XDR-TB were 50%. Compared with MDR-TB patients, those with XDR-TB had a higher risk of treatment failure (29% vs. 8%, respectively, P < 0.001). Unfavourable treatment outcomes were significantly associated with being male; having smear-positive disease; pulmonary cavities; failure, default or relapse after previous MDR-TB treatment; and a history of incarceration.

CONCLUSION:

More MDR-TB in Latvia is now also XDR-TB. This study identified several risk factors for XDR-TB and, for unfavourable treatment outcomes, highlighting the importance of early diagnosis and appropriate management of MDR-/XDR-TB.
Key words

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Language: En Journal: Public Health Action Year: 2014 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Language: En Journal: Public Health Action Year: 2014 Document type: Article